Glucagonostatic Potency of GLP-1 in Patients with Type 2 Diabetes, in Patients with Type 1 Diabetes, and Healthy Control Subjects
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Glucagonostatic Potency of GLP-1 in Patients with Type 2 Diabetes, in Patients with Type 1 Diabetes, and Healthy Control Subjects. / Bagger, Jonatan I.; Grøndahl, Magnus; Lund, Asger; Holst, Jens J; Vilsbøll, Tina; Knop, Filip K.
I: Diabetes, Bind 70, Nr. 4, 2021, s. 1347-1356.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Glucagonostatic Potency of GLP-1 in Patients with Type 2 Diabetes, in Patients with Type 1 Diabetes, and Healthy Control Subjects
AU - Bagger, Jonatan I.
AU - Grøndahl, Magnus
AU - Lund, Asger
AU - Holst, Jens J
AU - Vilsbøll, Tina
AU - Knop, Filip K
PY - 2021
Y1 - 2021
N2 - Hyperglucagonemia is a well-known contributor to diabetic hyperglycemia, and glucagon-like peptide-1 (GLP-1) suppresses glucagon secretion. Reduced inhibitory effects of glucose and GLP-1 on glucagon secretion may contribute to the hyperglucagonemia in diabetes and influence the success of GLP-1 receptor agonist therapy. We examined the dose-response relationship for GLP-1 on glucose-induced glucagon suppression in healthy individuals, patients with type 2 and type 1 diabetes. In randomized order, 10 healthy individuals with normal glucose tolerance, 10 patients with type 2 diabetes and 9 C-peptide negative patients with type 1 diabetes, underwent 4 separate stepwise glucose clamps (five 30-minute steps from fasting level to 15 mM plasma glucose) during simultaneous intravenous infusions of saline, 0.2, 0.4 or 0.8 pmol GLP-1/kg/min. In healthy individuals and patients with type 2 diabetes, GLP-1 potentiated the glucagon-suppressive effect of intravenous glucose in a dose-dependent manner. In patients with type 1 diabetes, no significant changes in glucagon secretion were observed during the clamps whether with saline or GLP-1 infusions. In conclusion, the glucagonostatic potency of GLP-1 during a stepwise glucose clamp is preserved in patients with type 2 diabetes, whereas our patients with type 1 diabetes were insensitive to the glucagonostatic effects of both glucose and GLP-1.
AB - Hyperglucagonemia is a well-known contributor to diabetic hyperglycemia, and glucagon-like peptide-1 (GLP-1) suppresses glucagon secretion. Reduced inhibitory effects of glucose and GLP-1 on glucagon secretion may contribute to the hyperglucagonemia in diabetes and influence the success of GLP-1 receptor agonist therapy. We examined the dose-response relationship for GLP-1 on glucose-induced glucagon suppression in healthy individuals, patients with type 2 and type 1 diabetes. In randomized order, 10 healthy individuals with normal glucose tolerance, 10 patients with type 2 diabetes and 9 C-peptide negative patients with type 1 diabetes, underwent 4 separate stepwise glucose clamps (five 30-minute steps from fasting level to 15 mM plasma glucose) during simultaneous intravenous infusions of saline, 0.2, 0.4 or 0.8 pmol GLP-1/kg/min. In healthy individuals and patients with type 2 diabetes, GLP-1 potentiated the glucagon-suppressive effect of intravenous glucose in a dose-dependent manner. In patients with type 1 diabetes, no significant changes in glucagon secretion were observed during the clamps whether with saline or GLP-1 infusions. In conclusion, the glucagonostatic potency of GLP-1 during a stepwise glucose clamp is preserved in patients with type 2 diabetes, whereas our patients with type 1 diabetes were insensitive to the glucagonostatic effects of both glucose and GLP-1.
U2 - 10.2337/db20-0998
DO - 10.2337/db20-0998
M3 - Journal article
C2 - 33722838
VL - 70
SP - 1347
EP - 1356
JO - Diabetes
JF - Diabetes
SN - 0012-1797
IS - 4
ER -
ID: 258893204